
Surge in ‘neglected' deadly parasite that destroys your organs sparks fears it will ‘inevitably' reach the UK
EXPERTS have sounded the alarm over the surge of a "neglected" parasite that can cause deadly liver failure.
Alveolar echinococcosis (AE) is a rare parasitic disease that spreads from animals to humans and is "of increasing concern worldwide" - but the recent rise in cases has sparked fears that it could reach the UK.
2
2
The "silently progressing and infiltrative disease" is caused by the parasite Echinococcus multilocularis, known as the fox parasite as it tends to infect foxes, as well as dogs.
While animals won't usually show any signs of infection, the parasite can cause serious illness in humans, who may pick it up from contact with fox or dog faeces or handling contaminated plants, soil or berries.
When the parasite enters the body, it can cause tumour-like growths - usually in the liver - that expand slowly over 10 to 15 years, until they cause symptoms such as stomach pain, weight loss and signs of liver failure.
Left untreated, the tapeworms may spread to other organs and can be fatal.
The World Health Organisation (WHO) previously listed AE as one of its 17 most "neglected" disease s in 2014, calling for more to be done to control it.
Swiss scientists have now revealed that cases of AE, though still rare, increased nearly three times over in a 30 year period.
They also revealed that the parasitical disease - once contained in Europe, China, Japan and Siberia - is now spreading to parts of Canada and the United States.
"Previously non-endemic regions such as North America and eastern central Europe are reporting an increasing number of AE patients," University Hospital Zurich scientists wrote in a report published by the US Centers for Disease Control and Prevention (CDC).
So far, there have been no known domestically acquired cases of E. multilocularis in the UK.
But as cases of the disease are increasingly spotted European regions, it has stoked fears that the parasite may infect animals and humans in the British Isles.
"It is almost inevitable that E.multilocularis will be introduced into the UK," veterinary surgeon Ian Wright warned in 2016.
The recent study included all patients who were treated for AE at Zurich University Hospital between 1973 and 2022, about 334 in total.
Researchers analysed patients' symptoms at diagnosis, AE stage, the treatment strategy used and resulting outcomes, and causes of death.
In 1993, there were about two cases of AE recorded by the institution, while in 2022 that number jumped to 14.
Out of the 334 patients, 151 had some type of surgery to remove the parasites while 315 received drug therapy with the medication benzimidazole.
Over the 50-year study period, 90 patients died but mostly from causes other than the parasitic infection.
Only 13 deaths were directly caused by AE, researchers found.
Researchers also found that people who'd contracted AE had lower survival rates compared with the general population five years after diagnosis - especially those who were diagnosed with AE later in life.
Symptoms of alveolar echinococcosis (AE)
AE is caused by tumor-like or cyst-like tapeworm larvae growing in the body.
AE usually involves the liver but can spread to other organs of the body.
Because the cysts are slow-growing, infection with AE may not produce any symptoms for many years.
Pain or discomfort in the upper abdominal region, weakness, and weight loss may occur as a result of the growing cysts.
Symptoms may mimic those of liver cancer and cirrhosis of the liver.
People who accidentally swallow the eggs of the Echinococcus multilocularis tapeworm are at risk for infection.
People at high risk include trappers, hunters, veterinarians, or others who have contact with wild foxes, or coyotes, or their stool, or household dogs and cats that eat wild rodents infected with AE.
Humans can be exposed to these eggs by ingesting food contaminated with stool from foxes, such as herbs, greens, or berries, or by petting dogs or cats who have the tapeworm and then touching their mouth.
Source: CDC
But AE didn't seem to be the main driver of their shortened life expectancy.
The researchers also found that without benzimidazole therapy, 90 per cent of patients died within 10 years of contracting the disease but with long-term therapy, they were able to prevent a disease from worsening.
They also concluded that removing all of the parasite-damaged tissue in the body through surgery could improve overall survival but could not slow down the disease.
The study authors speculated that the "the gradual decline of relative survival five years after diagnosis could reflect a generally sicker population".
"In our cohort, the rise of annual AE cases was accompanied by a substantial increase in incidental findings and a shift toward earlier stages, although symptomatic patients with an advanced disease stage remained the majority," report authors said.
Alveolar echinococcosis in the UK
While there have been no known domestically acquired cases of E. multilocularis in the UK, the parasitic disease was the cause of death of a woman in 1954, according to the British Pest Control Association.
She had never left the country but is thought to have picked up the parasite after eating unpasteurised Swiss cheese.
A further case was reported in 2002 in a man from Afghanistan who had recently moved to the UK from Pakistan.
In 2022, 27 European countries reported 731 echinococcosis cases, according to the European Centre for Disease Prevention and Control (ECDC).
In the last decade, cases have doubled in France, Germany, Austria and Switzerland.
Baltic countries have also seen an increase in cases, while the disease has become established in regions of Denmark, Sweden, Norway, and the north-western coast of France.
The only countries currently free of E. multilocularis are the UK, Ireland, Malta and Finland.
To remain disease-free, all them conduct yearly fox surveillance programmes for the parasite and report their findings to the European Commission once a year.
There is a risk that dogs who travel with their owners to regions where the parasite is endemic could pick up the parasite.
Writing in Improve Veterinary Practice, Ian Wright said: "The Pet travel scheme currently still requires dogs to be treated with praziquantel between one and five days before entry to the UK.
"This simple treatment has currently prevented endemic foci from developing, and as such it remains vital.
"It has been demonstrated that if this compulsory treatment is abandoned altogether, then it is almost inevitable that E.multilocularis will be introduced into the UK.
"For every 10,000 dogs travelling on a short visit to an endemic country such as Germany, the probability of at least one returning with the parasite is approximately 98 per cent.
"This probability increases to over 99 per cent if dogs have been longer term residents.
"Although the one to five day rule has provided protection against this, it does allow a window of opportunity for infection.
"If E.multilocularis is allowed entry into the UK, the large fox and microtine vole population will make the prevention of endemic E.multilocularis difficult, if not impossible to achieve."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Daily Mirror
10 hours ago
- Daily Mirror
Covid Nimbus variant with painful symptom UK hospital cases rise
New figures show the viral infection is on the rise after hitting UK shores - with NHS advising 'stay home' with symptoms Covid cases being admitted to hospital have shown a big increase as a new variant with a 'painful' symptom hit the UK. Doctors have said the new strain of Covid - codenamed Nimbus has one specific symptom. Cases of the variant have been found in the UK as it starts to dominate across the world, having been detected in January. The increase in cases has seen the World Health Organisation say it is monitoring the new variety, also known as NB.1.8.1, closely. New figures updated by the UK Health Security Agency show that the number of hospitalistations in the UK has risen almost 10 per cent in the last week for which figures are available. The statistics show a 947 patients admitted with Covid in the week to May 31 - an increase of 9.4 per cent on the preceding week. Number of detected cases, and bearing in mind there is no widespread testing going on, is 1,211 in the week to June 4, a rise of 6.9 per cent. Number of deaths was 63, in the week to May 30, down 12.5 per cent on the previous week. The NHS advice is currently that if a person believes they have Covid they should stay at home. Nimbus is now the dominant strain in China and makes up a third of cases in the USA, while it is being blamed for a spike in cases in Australia. The mutated Nimbus strain is able to spread more easily and more infectious than previous variants. Vaccines and previous infection have been found to be about half as effective at blocking Nimbus as some other strains. A World Health Organisation spokesman said: 'Currently approved COVID-19 vaccines are expected to remain effective against this variant against symptomatic and severe disease. Despite a concurrent increase in cases and hospitalizations in some countries where NB.1.8.1 is widespread, current data do not indicate that this variant leads to more severe illness than other variants in circulation.' Patients have reported this variant giving them 'razor blade throat', a very sore throat which has left some people with a hoarse voice. Director & Superintendent Pharmacist, Prescription Doctor, Mohamed Imran Lakhi, said: 'People commonly report a severe sore throat, persistent fatigue, mild cough, fever, muscle aches, and nasal congestion. Some also experience digestive issues like nausea or diarrhoea, which isn't always typical with Covid variants.' According to Dr Naveed Asif, GP at The London General Practice, the NB.1.8.1 variant has a distinctive symptom, a severe sore throat known as a 'razor blade sensation'. This is a sharp, stabbing pain when you swallow, often at the back of the throat. It can be treated in the same way with rest, fluids and painkillers. If your symptoms persist or get worse, or if you are worried about you or someone else you can speak to a GP or call 111. If someone is in serious distress, for example struggling to breathe, you should call 999. The UKHSA said: 'You might have seen news or social media conversations about the COVID-19 variant NB.1.8.1, which you might know as the 'Nimbus variant'. NB.1.8.1 has been detected in small numbers in the UK to date, but international data suggests that it is growing as a proportion of al Covid-19 cases. Based on the available information so far however, there is no evidence to suggest that this variant causes more severe disease than previous variants, of that the vaccines in current use will be less effective against it.' The UKHSA has confirmed the emergence of the 'Nimbus' variant in the UK, highlighting its relatively rare status but noting its faster growth rate compared to other Covid-19 cases globally. Regions hit by NB.1.8. 1 have seen rises in cases and hospital admissions, however, health professionals have yet to ascertain whether it leads to more severe health complications than previous strains. UKHSA suggests that if you must leave your home whilst having symptoms of a respiratory infection and either a fever or feeling poorly, you're advised to "avoid close contact with anyone who you know is at higher risk of becoming seriously unwell, especially those whose immune system means that they are at higher risk of serious illness, despite vaccination." UKHSA guidance on minimising the risk of transmitting infection to others: Wear a well-fitting face covering made with multiple layers or a surgical face mask Avoid crowded places such as public transport, large social gatherings, or anywhere that is enclosed or poorly ventilated Taking any exercise outdoors in places where you will not have close contact with other people Covering your mouth and nose when you cough or sneeze; wash your hands frequently with soap and water for 20 seconds or use hand sanitiser after coughing, sneezing and blowing your nose and before you eat or handle food; avoid touching your face. Symptoms include: severe sore throat fatigue mild cough fever muscle aches congestion


Reuters
a day ago
- Reuters
WHO warns of spread of cholera outbreak from Sudan to Chad refugee camps
GENEVA, June 13 (Reuters) - The World Health Organization warned on Friday that cholera cases in Sudan are set to rise and could spread to neighbouring countries, including Chad, which hosts hundreds of thousands of refugees from Sudan's civil war in crowded conditions. The more than two-year-old war between the Sudanese army - which took full control of Khartoum state this week - and the paramilitary Rapid Support Forces has spread hunger and disease and destroyed most health facilities. Drone attacks in recent weeks have interrupted electricity and water supplies in the capital Khartoum, driving up cases there. "Our concern is that cholera is spreading," Dr Shible Sahbani, WHO Representative for Sudan, told reporters in Geneva by video link from Port Sudan. He said that cholera had reached 13 states in Sudan, including North and South Darfur which border Chad, and that 1,854 people had already died in the latest wave as the dangerous, rainy season sets in. "We assume that if we don't invest in the prevention measures, in surveillance, in the early warning system, in vaccination and in educating the population, for sure, the neighbouring countries, but not only that, it can maybe spread to the sub-region," he said. He called for humanitarian corridors and temporary ceasefires to allow mass vaccination campaigns against cholera and other disease outbreaks such as Dengue fever and malaria. Cholera, a severe, potentially fatal diarrhoeal disease, spreads quickly when sewage and drinking water are not treated adequately. Sahbani said that this posed a high risk for Sudanese refugees, including some who had survived attacks on a displacement camp in Darfur, and who are living in cramped, makeshift border sites on the Chadian side of the border. "In overcrowded, unsanitary conditions, a potential outbreak could be devastating," said François Batalingaya, U.N. Resident and Humanitarian Coordinator in Chad at the same briefing, describing the conditions for some 300,000 people stranded there with few aid services due to funding shortages. The disease has not yet been confirmed in Chad, although a WHO spokesperson said that suspected cases had been reported in Geneina, Sudan which is just 10 km (6.2 miles) away. Sahbani also said that disease surveillance was low on the Libyan border and that it could possibly spread there. Case fatality rates have fallen in recent weeks in and around the capital Khartoum thanks to an oral cholera vaccination campaign that started this month, Sahbani said.


Scotsman
a day ago
- Scotsman
Biofilm prevention leader Remora announces groundbreaking partnership with global textile chemical innovator
Award-winning Scottish biotechnology company Remora has announced a major milestone in its commercial journey after signing a new long-term licensing agreement with Swiss-based Beyond Surface Technologies (BST) to bring its revolutionary biofilm prevention technology to the global textile market. Sign up to our daily newsletter – Regular news stories and round-ups from around Scotland direct to your inbox Sign up Thank you for signing up! Did you know with a Digital Subscription to The Scotsman, you can get unlimited access to the website including our premium content, as well as benefiting from fewer ads, loyalty rewards and much more. Learn More Sorry, there seem to be some issues. Please try again later. Submitting... Award-winning Scottish biotechnology company Remora has announced a major milestone in its commercial journey after signing a new long-term licensing agreement with Swiss-based Beyond Surface Technologies (BST) to bring its revolutionary biofilm prevention technology to the global textile market. The partnership will see BST – a specialist in sustainable textile chemistry – integrate the patented Remora® technology into its green chemical formulations for use across performance apparel, outdoor garments and technical fabrics. Advertisement Hide Ad Advertisement Hide Ad Biofilms – invisible layers of microorganisms that adhere to fabrics – are a widespread issue in the textile sector. On performance garments in particular, they cause persistent odours, staining, and material degradation, even after repeated washing. They also pose risks of skin irritation and contamination. Matthias Foessel, Co-founder and CEO of Beyond Surface Technologies Remora® technology offers a breakthrough solution. Developed using a scientifically engineered molecule inspired by red seaweed's natural defense mechanisms, it prevents biofilm formation at source, without relying on toxic antimicrobial agents. Remora's collaboration with BST will support the sustainable creation of cleaner, fresher and longer-lasting textiles. The technology can be used at multiple stages of the supply chain. Dr Yvonne Davies, Chief Commercial Officer at Remora, said: 'This partnership with BST is a transformational step for Remora and a breakthrough moment for the textile industry. Our Remora® technology offers a sustainable, scientifically proven alternative to toxic biocidal treatments and will help brands tackle persistent odour, staining and material degradation caused by biofilms. 'Through BST's extensive global supply chain relationships and deep expertise in green chemistry, we now have a clear route to market with some of the biggest names in fashion, performance wear and technical textiles. This collaboration doesn't just scale our technology, it unlocks its full potential to support a cleaner, safer and more sustainable future for textiles.' Advertisement Hide Ad Advertisement Hide Ad Matthias Foessel, Co-founder and CEO of Beyond Surface Technologies, said: 'We are excited to bring this remarkable marine-inspired technology for biofilm prevention to the textile industry. It offers a unique way to keep fabrics and garments cleaner and fresher for longer. 'We're very pleased to have signed this collaboration with Remora, based on a Unilever patent portfolio. This partnership marks another important milestone in our mission to advance chemistry with reduced environmental impact - without compromising on performance.' Originally developed through a decade-long R&D collaboration with Unilever and leading UK universities, Remora's technology now has a direct route into commercial textile markets via BST's formulation expertise and global customer network – which includes many of the world's best-known fashion and sportswear brands.